Literature DB >> 29110761

The Cell Biology of APOL1.

John F O'Toole1, Leslie A Bruggeman2, Sethu Madhavan2, John R Sedor3.   

Abstract

The association of variants in the APOL1 gene, which encodes apolipoprotein L1 (APOL1), with progressive nondiabetic kidney diseases in African Americans has prompted intense investigation into the function(s) of APOL1. APOL1 is an innate immune effector that protects human beings from infection by some trypanosomal parasites. We review the data characterizing APOL1 trypanolytic function, which has been a basis for studies of APOL1 function in mammalian cells. Subsequently, we discuss the studies that use animal models, mammalian cell culture models, and kidney biopsy tissue to discover the mechanisms of variant APOL1-associated kidney diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  African American; Kidney disease; cytotoxicity; ion channel; trypanosome

Mesh：

Substances：

Year:  2017        PMID： 29110761      PMCID： PMC5678957          DOI： 10.1016/j.semnephrol.2017.07.007

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN： 0270-9295            Impact factor:   5.299


  58 in total

1.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

2.  Renal epithelium is a previously unrecognized site of HIV-1 infection.

Authors:  Leslie A Bruggeman; Michael D Ross; Nozomu Tanji; Andrea Cara; Steven Dikman; Ronald E Gordon; Godfrey C Burns; Vivette D D'Agati; Jonathan A Winston; Mary E Klotman; Paul E Klotman
Journal:  J Am Soc Nephrol       Date:  2000-11       Impact factor: 10.121

3.  Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene.

Authors:  P N Duchateau; C R Pullinger; M H Cho; C Eng; J P Kane
Journal:  J Lipid Res       Date:  2001-04       Impact factor: 5.922

4.  The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.

Authors:  B T Lee; V Kumar; T A Williams; R Abdi; A Bernhardy; C Dyer; S Conte; G Genovese; M D Ross; D J Friedman; R Gaston; E Milford; M R Pollak; A Chandraker
Journal:  Am J Transplant       Date:  2012-04-04       Impact factor: 8.086

5.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

6.  Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.

Authors:  Lijun Ma; Gregory S Shelness; James A Snipes; Mariana Murea; Peter A Antinozzi; Dongmei Cheng; Moin A Saleem; Simon C Satchell; Bernhard Banas; Peter W Mathieson; Matthias Kretzler; Ashok K Hemal; Lawrence L Rudel; Snezana Petrovic; Allison Weckerle; Martin R Pollak; Michael D Ross; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

7.  APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.

Authors:  Leslie A Bruggeman; Zhenzhen Wu; Liping Luo; Sethu M Madhavan; Martha Konieczkowski; Paul E Drawz; David B Thomas; Laura Barisoni; John R Sedor; John F O'Toole
Journal:  J Am Soc Nephrol       Date:  2016-03-29       Impact factor: 10.121

8.  ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death.

Authors:  Siqin Zhaorigetu; Guanghua Wan; Ramesh Kaini; Zeyu Jiang; Chien-an A Hu
Journal:  Autophagy       Date:  2008-11-23       Impact factor: 16.016

9.  Plasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort.

Authors:  Julia Kozlitina; Haihong Zhou; Patricia N Brown; Rory J Rohm; Yi Pan; Gulesi Ayanoglu; Xiaoyan Du; Eric Rimmer; Dermot F Reilly; Thomas P Roddy; Doris F Cully; Thomas F Vogt; Daniel Blom; Maarten Hoek
Journal:  J Am Soc Nephrol       Date:  2016-03-22       Impact factor: 10.121

10.  Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses.

Authors:  Paul J McLaren; Ali Gawanbacht; Nitisha Pyndiah; Christian Krapp; Dominik Hotter; Silvia F Kluge; Nicola Götz; Jessica Heilmann; Katharina Mack; Daniel Sauter; Danielle Thompson; Jérémie Perreaud; Antonio Rausell; Miguel Munoz; Angela Ciuffi; Frank Kirchhoff; Amalio Telenti
Journal:  Retrovirology       Date:  2015-05-16       Impact factor: 4.602
View more
  15 in total

Review 1.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

2.  APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.

Authors:  Adriana M Hung; Shailja C Shah; Alexander G Bick; Zhihong Yu; Hua-Chang Chen; Christine M Hunt; Frank Wendt; Otis Wilson; Robert A Greevy; Cecilia P Chung; Ayako Suzuki; Yuk-Lam Ho; Elvis Akwo; Renato Polimanti; Jin Zhou; Peter Reaven; Philip S Tsao; J Michael Gaziano; Jennifer E Huffman; Jacob Joseph; Shiuh-Wen Luoh; Sudha Iyengar; Kyong-Mi Chang; Juan P Casas; Michael E Matheny; Christopher J O'Donnell; Kelly Cho; Ran Tao; Katalin Susztak; Cassianne Robinson-Cohen; Sony Tuteja; Edward D Siew
Journal:  JAMA Intern Med       Date:  2022-04-01       Impact factor: 21.873

3.  Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes.

Authors:  Zhongyang Zhang; Zeguo Sun; Jia Fu; Qisheng Lin; Khadija Banu; Kinsuk Chauhan; Marina Planoutene; Chengguo Wei; Fadi Salem; Zhengzi Yi; Ruijie Liu; Paolo Cravedi; Haoxiang Cheng; Ke Hao; Philip J O'Connell; Shuta Ishibe; Weijia Zhang; Steven G Coca; Ian W Gibson; Robert B Colvin; John Cijiang He; Peter S Heeger; Barbara Murphy; Madhav C Menon
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

Review 4.  APOL1 polymorphisms and kidney disease: loss-of-function or gain-of-function?

Authors:  Leslie A Bruggeman; John F O'Toole; John R Sedor
Journal:  Am J Physiol Renal Physiol       Date:  2018-10-17

5.  Effect of a Single Apolipoprotein L1 Gene Nephropathy Variant on the Risk of Advanced Lupus Nephritis in Brazilians.

Authors:  Gisele Vajgel; Suelen Cristina Lima; Diego Jeronimo S Santana; Camila B L Oliveira; Denise Maria N Costa; Pamela J Hicks; Maria Alina G M Cavalcante; Carl D Langefeld; Lucila Maria Valente; Sergio Crovella; Gianna Mastroianni Kirsztajn; Barry I Freedman; Paula Sandrin-Garcia
Journal:  J Rheumatol       Date:  2019-11-15       Impact factor: 4.666

Review 6.  Kidney disease and APOL1.

Authors:  Aminu Abba Yusuf; Melanie A Govender; Jean-Tristan Brandenburg; Cheryl A Winkler
Journal:  Hum Mol Genet       Date:  2021-04-26       Impact factor: 6.150

7.  Podocyte density is reduced in kidney allografts with high-risk APOL1 genotypes at transplantation.

Authors:  Dhruti P Chen; Ziad S Zaky; Jesse D Schold; Leal C Herlitz; Rasha El-Rifai; Paul E Drawz; Leslie A Bruggeman; Laura Barisoni; Susan L Hogan; Yichun Hu; John F O'Toole; Emilio D Poggio; John R Sedor
Journal:  Clin Transplant       Date:  2021-02-10       Impact factor: 2.863

8.  APOL1 Risk Variants Associated with Serum Albumin in a Population-Based Cohort Study.

Authors:  Ninad S Chaudhary; Hemant K Tiwari; Bertha A Hidalgo; Nita A Limdi; Richard J Reynolds; Mary Cushman; Neil A Zakai; Leslie Lange; Suzanne E Judd; Cheryl A Winkler; Jeffrey B Kopp; Orlando M Gutiérrez; Marguerite R Irvin
Journal:  Am J Nephrol       Date:  2022-01-31       Impact factor: 4.605

9.  APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.

Authors:  Leslie A Bruggeman; Zhenzhen Wu; Liping Luo; Sethu Madhavan; Paul E Drawz; David B Thomas; Laura Barisoni; John F O'Toole; John R Sedor
Journal:  PLoS One       Date:  2019-10-29       Impact factor: 3.240

10.  APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress.

Authors:  Hidefumi Wakashin; Jurgen Heymann; Hila Roshanravan; Parnaz Daneshpajouhnejad; Avi Rosenberg; Myung Kyun Shin; Maarten Hoek; Jeffrey B Kopp
Journal:  BMC Nephrol       Date:  2020-08-27       Impact factor: 2.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.